Article citationsMore>>

Ofotokun, I., Sheth, A.N., Sanford, S.E., et al. (2012) A Switch in Therapy to a Reverse Transcriptase Inhibitor Sparing Combination of Lopinavir/Ritonavir and Raltegravir in Virologically Suppressed HIV-Infected Patients: A Pilot Randomized Trial to Assess Efficacy and Safety Profile: The KITE Study. AIDS Research and Human Retroviruses, 28, 1196-1206. http://dx.doi.org/10.1089/aid.2011.0336

has been cited by the following article:

• TITLE: Changes in Bone Mineral Density through 96 Weeks in Antiretroviral-Naïve HIV-1 Infected Patients Receiving Abacavir/Lamivudine and Raltegravir in the SHIELD Trial

  AUTHORS: Linda Battalora, Amy Thomas, Brian Wine, Belinda Ha, Benjamin Young

  KEYWORDS: Bonedensity; Abacavir; HIV; Integrase; Lamivudine; Raltegravir

  JOURNAL NAME: World Journal of AIDS, Vol.4 No.1, March 4, 2014

  ABSTRACT: Decreased bone mineral density (BMD) and osteoporotic fractures are areas of increasing concern among HIV-infected persons. Particular concern is the rapid decline in BMD after initiation of antiretroviral treatment (ART). This report describes DEXA-assessed changes in BMD and body fat in a study of fifteen antiretroviral-na?ve adults initiating abacavir/lamivudine and raltegravir for 96 weeks. Median percent changes from baseline at weeks 48 and 96 in BMD were 0.29% and -0.11% (spine); -1.25% and -1.75% (left hip). Median percent changes from baseline in fat from baseline were -0.82% and -3.04% (trunk); 2.12% and 2.01% (limb). In this pilot study, ABC/3TC + RAL treatment had limited impact on BMD and body fat.